New England Journal of Medicine November 16, 2026

Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age

Ania M. Jastreboff, Nina M. Harder-Lauridsen, Michelle Van Name, et al.

Bottom Line

In a phase 3 trial involving children aged 6 to under 12 years with obesity, once-weekly subcutaneous semaglutide treatment yielded a 13.5% mean reduction in BMI at 68 weeks, significantly greater than the 2.7% increase seen with placebo.

Key Findings

1. At week 68, the mean percent change in BMI was -13.5% with semaglutide and 2.7% with placebo (estimated between-group difference, -16.2 percentage points; 95% CI, -19.4 to -12.9; P<0.001).
2. At week 104, the percent change in BMI remained lower with semaglutide (-9.4%) compared to placebo (+8.4%) (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3).
3. A reduction in BMI category at week 68 occurred in 79% of the participants in the semaglutide group versus 23% in the placebo group (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001).
4. At week 68, BMI dropped below the 95th percentile threshold for obesity in 38% of semaglutide participants, compared to only 2% of placebo participants.
5. Adverse events were frequent in both groups (96% semaglutide vs. 93% placebo); gastrointestinal events were most common and led to discontinuation in just 1 participant in the semaglutide group.

Study Design

Design
RCT
Double-Blind
Sample
167
Patients
Duration
104 wk
Median
Setting
Multicenter
Population Children 6 to <12 years of age with obesity
Intervention Once-weekly subcutaneous semaglutide plus counseling for lifestyle modification for 104 weeks
Comparator Placebo plus counseling for lifestyle modification for 104 weeks
Outcome Percent change in body-mass index (BMI) from baseline to week 68

Study Limitations

• The study population was predominantly white, potentially limiting the generalizability of the findings to more diverse populations.
• The trial lacked baseline screening for eating disorders, an important consideration in pediatric weight management.
• The high discontinuation rate of injections in the placebo arm by week 104 complicates long-term tolerability and efficacy comparisons.
• The study design required continuous medication to maintain effects, leaving questions regarding the trajectory of BMI after full cessation.

Clinical Significance

This trial robustly demonstrates the efficacy and tolerability of once-weekly semaglutide in pre-adolescent children (6 to <12 years) with obesity. Given the paucity of durable, efficacious pharmacologic interventions for this highly vulnerable demographic, these findings support GLP-1 receptor agonism as a powerful tool to reverse severe childhood obesity trajectories before adulthood.

Historical Context

Childhood obesity is a chronic neurometabolic disease with limited treatment options. Prior to the STEP Young trial, once-weekly semaglutide had established a new standard of care for adolescents (STEP TEENS) and adults (STEP 1-5 trials), achieving remarkable weight reductions. However, younger children (under 12 years) only had older, less effective, or daily-injection options such as liraglutide (SCALE Kids trial). This 2026 study addressed the critical gap by validating the use of the highly effective semaglutide 2.4 mg platform in a younger pediatric cohort.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What is the primary mechanism of action of semaglutide, and how does targeting this specific endocrine pathway produce significant weight loss in pediatric patients compared to lifestyle-only interventions?

Key Response

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It promotes weight loss by delaying gastric emptying and acting directly on the hypothalamus to increase satiety and decrease hunger. Understanding this incretin effect helps students connect basic gastrointestinal endocrinology to the clinical outcomes observed in modern obesity management.

Resident
Resident

Given the significant BMI reduction seen in this trial, what are the most common adverse effects you must counsel parents about when initiating semaglutide in a young child, and how would you manage them clinically?

Key Response

The most frequent adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation. Residents need to know how to dose-titrate slowly and counsel families on eating smaller, more frequent meals to mitigate these side effects and prevent early discontinuation of the medication.

Fellow
Fellow

In prepubertal children aged 6 to 11 with severe obesity, how might the profound weight loss achieved with semaglutide impact longitudinal growth velocity, bone mineral accretion, and pubertal timing, and what specific monitoring protocols should be implemented?

Key Response

Rapid weight loss in prepubertal children can theoretically alter linear growth, bone density, and the physiological onset of puberty. Fellows in pediatric endocrinology must consider these subspecialty-level impacts and design long-term monitoring strategies, such as tracking bone age and pubertal staging, rather than just monitoring BMI.

Attending
Attending

How should we navigate the ethical and practical dilemmas of starting a potentially lifelong, expensive subcutaneous medication in a 6-year-old child, particularly considering the rebound weight gain observed in adult trials upon drug cessation?

Key Response

Attendings must balance the immediate, profound metabolic benefits with long-term realities. This involves complex shared decision-making with families regarding cost, injection fatigue, adherence, and the reality that obesity is a chronic disease likely requiring indefinite therapy to maintain the 13.5% BMI reduction.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

How might the use of BMI percentage reduction as the primary endpoint limit our understanding of semaglutide's true effect on body composition in growing prepubertal children, and what alternative imaging or biomarker endpoints should future trials incorporate?

Key Response

BMI is an imperfect proxy for adiposity in growing children. A researcher would critique the potential lack of dual-energy X-ray absorptiometry (DXA) or advanced metabolic phenotyping to differentiate fat mass loss from critical lean muscle and bone mass alterations during this crucial developmental window.

Journal Editor
Journal Editor

To what extent does the unblinding risk due to distinct gastrointestinal side effects in the semaglutide arm threaten the internal validity of the efficacy outcomes, and how adequately did the authors address missing data through their chosen estimand framework?

Key Response

GI side effects often functionally unblind GLP-1 trials. An editor would heavily scrutinize how the trial handled treatment-policy estimands and missing data (e.g., using jump-to-reference imputation) to ensure the reported BMI reduction wasn't artificially inflated by missingness or placebo arm dropout.

Guideline Committee
Guideline Committee

The 2023 AAP guidelines on childhood obesity strongly recommend pharmacotherapy for children aged 12 and older; based on this 68-week Phase 3 data, should the age threshold for initiating GLP-1 agonists be formally lowered to 6 years, and what evidence grade would support this update?

Key Response

Current AAP guidelines support adjunct pharmacotherapy starting at age 12. This randomized, placebo-controlled trial provides high-quality (Level A) evidence that could justify lowering the treatment threshold to age 6 for severe pediatric obesity, forcing a major paradigm shift in pediatric obesity clinical practice guidelines.

Clinical Landscape

Noteworthy Related Trials

2020

SCALE Teens Trial

n = 251 · NEJM

Tested

Liraglutide 3.0 mg daily

Population

Adolescents (12-18 years) with obesity

Comparator

Placebo

Endpoint

Change in BMI standard-deviation score at week 56

Key result: Liraglutide significantly reduced the BMI standard-deviation score compared to placebo but had more gastrointestinal adverse events.
2022

STEP TEENS Trial

n = 201 · NEJM

Tested

Semaglutide 2.4 mg once weekly

Population

Adolescents (12-18 years) with obesity

Comparator

Placebo

Endpoint

Percentage change in BMI from baseline to week 68

Key result: Semaglutide resulted in a 16.1% reduction in BMI compared to a 0.6% increase with placebo.
2024

SCALE Kids Trial

n = 82 · NEJM

Tested

Liraglutide 3.0 mg daily

Population

Children 6 to <12 years of age with obesity

Comparator

Placebo

Endpoint

Percentage change in BMI at week 56

Key result: Liraglutide led to a 5.8% reduction in BMI compared to a 1.6% increase with placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis
↑